Steven Cohen Arbutus Biopharma Corp Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $177,450 - $266,700	105,000 New	105,000 $262,000
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $2.78 Million - $4.13 Million	-895,200 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $277,720 - $484,176	-104,800 Reduced 10.48%	895,200 $3.84 Million
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $94,250 - $132,327	-37,700 Reduced 3.63%	1,000,000 $3.03 Million
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $3.26 Million - $5.02 Million	1,037,700 New	1,037,700 $3.46 Million
Q1 2020 May 15, 2020	SELL	$1.01 - $3.42 $1.92 Million - $6.49 Million	-1,897,284 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $1.65 Million - $5.48 Million	1,897,284 New	1,897,284 $5.27 Million
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $999,714 - $1.73 Million	-224,655 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $763,827 - $1.57 Million	224,655	224,655 $1.39 Million

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.